BRCA1 and neoplasm: More than half of the BRCA1/2 tumor analyses were performed on an Illumina platform (Illumina, Inc., San Diego, CA, USA) (n = 262; 52.2%), 15.1% on an Ion Torrent platform (Thermo Fisher Scientific Inc., Waltham, MA, USA), and in more than 30% of the BRCA1/2 tumor analyses, the platform used was not specified (n = 156; 31.1%) (Supplementary Table S4).